SEC Form 4 · accession 0001562180-18-001252
PALVELLA THERAPEUTICS, INC. · PVLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allan Reine
Officer — Chief Financial Officer
Period of report
Feb 20, 2018
Accepted (ET)
Feb 26, 2018 · 7:15 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583648
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to buy)F1 | $8.56 | Feb 20, 2018 | A | 53,833 | A | — | Feb 20, 2028 | Common Stock | 53,833 | 53,833 | D |
| Stock Options (Right to buy)F2 | $5.00 | Feb 20, 2018 | A | 50,000 | A | — | Aug 8, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The option vests as to 25% of the option shares on January 1, 2019 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.
- F2On August 9, 2017, the reporting person was granted an option to purchase up to a maximum of 50,000 shares of common stock of which 50,000 shares were earned based on the reporting person's achievement of his 2017 personal goals as certified by the Compensation Committee of the Board of Directors on February 20, 2018. The earned shares vest as to 25% on February 20, 2019 and the remainder vests as to an additional 6.25% quarterly thereafter beginning on the last day of the next calendar quarter.